1. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine.
- Author
-
Peek LJ, Brandau DT, Jones LS, Joshi SB, and Middaugh CR
- Subjects
- Animals, Antigens, Protozoan, Chemistry, Pharmaceutical, Drug Stability, Malaria Vaccines standards, Protozoan Proteins standards, Malaria Vaccines chemical synthesis, Plasmodium falciparum, Protozoan Proteins chemical synthesis
- Abstract
Region II of the erythrocyte-binding antigen (EBA-175 RII) has been identified as a promising target for a malaria vaccine. A systematic approach to identify optimal preformulation conditions of a non-glycosylated (NG) antigen, EBA-175 RII-NG, has been developed. This approach consists of development of an empirical temperature/pH phase diagram, high throughput stabilizer screening and aluminum salt adjuvant adsorption studies. Using these physical methods, we developed a stable formulation for EBA-175 RII-NG at pH 6.0 with sucrose and Brij 35 as stabilizers and Adju-Phos as an adjuvant. This approach should be generally applicable to guiding the development of stable vaccine formulations.
- Published
- 2006
- Full Text
- View/download PDF